Pharmaceuticals Mexico

Mexico Migraine Drugs Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

Mexico Migraine Drugs Market Industry Trends and Forecast to 2034: Segmented by (Drug Class, Use, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Mexico · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $136.4 Mn Placeholder estimate
Estimate 2025 $147.2 Mn 1.7% of the global market
Projected 2034 $291.7 Mn 98.2% Adds $144.6 Mn over 9 forecast years
CAGR 2025–2034 7.9% Faster than 44% of 180 Pharmaceuticals markets here
Key players 6 +1
  • Mexico is 1.68% of the global market.
  • In Latin America, the largest is Ecuador at $194.7 Mn.
  • Fastest growing: Brazil at 8.9% a year.
  • Mexico ranks 3rd of 3 by size in Latin America.

Market size projection

Mexico

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$144.6 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Migraine Drugs Market market size by year, Mexico
YearMarket sizeChange that yearSince 2025
2024 (estimate) $136.4 Mn — —
2025 (base) $147.2 Mn +$10.8 Mn —
2026 (forecast) $158.8 Mn +$11.6 Mn +7.9%
2027 (forecast) $171.3 Mn +$12.5 Mn +16.4%
2028 (forecast) $184.9 Mn +$13.5 Mn +25.6%
2029 (forecast) $199.5 Mn +$14.6 Mn +35.5%
2030 (forecast) $215.2 Mn +$15.8 Mn +46.3%
2031 (forecast) $232.2 Mn +$17.0 Mn +57.8%
2032 (forecast) $250.6 Mn +$18.3 Mn +70.3%
2033 (forecast) $270.4 Mn +$19.8 Mn +83.7%
2034 (forecast) $291.7 Mn +$21.4 Mn +98.2%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Mexico Migraine Drugs Market Analysis at a glance
Market size, 2025$147.2 Mn placeholder estimate
Forecast, 2034$291.7 Mn placeholder estimate
Growth (CAGR), 2025–20347.9% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsDrug class, use and end user (see all)
Key playersPfizer Inc., AbbVie Inc., Teva Pharmaceutical, Eli Lilly and Company, Amgen Inc. and 1 more (see all)
Regulator in MexicoCOFEPRISSource: COFEPRIS. Checked 14 Nov 2026.
Active clinical trials7 in MexicoSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Mexico. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Mexico Migraine Drugs Market Analysis Executive Summary

Migraine drugs stop or prevent migraine attacks, including newer CGRP-blocking medicines and triptans.

Key segments of the migraine Drugs market include drug class (CGRP Antibodies, Gepants and Triptans) and use (Acute Treatment and Prevention).

Bar chart: Mexico Migraine Drugs market size, 2024–2034, placeholder estimates. $136.4 Mn in 2024, $147.2 Mn in 2025 and $291.7 Mn in 2034, 7.9% CAGR.
Mexico Migraine Drugs market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Mexico Migraine Drugs Market Dynamics

Market Growth Drivers

An ageing population, more people living with brain and nerve diseases, better diagnosis and the first disease-modifying treatments are driving the migraine Drugs market.

Opportunity

Biomarker-guided treatment, earlier diagnosis and new device-based therapies give the migraine Drugs market strong room to grow.

Market Restraints

Hard-to-reach brain targets, high failure rates in trials, side effects and high prices for new therapies hold back the migraine Drugs market.

Competitive Landscape for Migraine Drugs Market in Mexico

The migraine Drugs market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Migraine Drugs Market in Mexico

Migraine Drugs in Mexico: rules, payment and research

Medicines need a sanitary registration from COFEPRIS before sale.⁠[1] Public care comes through IMSS for formal workers, ISSSTE for public employees, and IMSS-Bienestar for people without social security.⁠[2] ClinicalTrials.gov lists 7 studies on Migraine Drugs that are recruiting, active or about to start in Mexico.⁠[3]

[1] COFEPRIS. Checked 14 Nov 2026.

[2] Mexican Social Security Institute (IMSS). Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Mexico. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for migraine Drugs. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Mexico.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Migraine Drugs right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Migraine Drugs in context

Mexico compared

  • Health spending per person: 761 US$ per person (2023). World: 1,317 US$ per person (2023). 2nd highest of the 4 countries we cover in Latin America.[1]
  • Doctors: 2.59 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). Highest of the 4 countries we cover in Latin America.[2]
  • People aged 65 and over: 8.5% of people (2025). World: 10.4% of people (2025). 3rd highest of the 4 countries we cover in Latin America.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 16 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 17 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 17 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Migraine Drugs market in Mexico?
Placeholder estimate: about $147.2 Mn in 2025, rising to about $291.7 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Migraine Drugs market in Mexico growing?
Placeholder estimate: about 7.9% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Migraine Drugs market report cover?
The report splits the market by drug class (CGRP Antibodies, Gepants, Triptans, Ditans and more), use (Acute Treatment, Prevention) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Migraine Drugs market?
Key players include Pfizer Inc., AbbVie Inc., Teva Pharmaceutical, Eli Lilly and Company, Amgen Inc. and Lundbeck.
What is driving the Migraine Drugs market?
An ageing population, more people living with brain and nerve diseases, better diagnosis and the first disease-modifying treatments are driving the migraine Drugs market.
Who regulates Migraine Drugs in Mexico?
Medicines need a sanitary registration from COFEPRIS before sale. Source: COFEPRIS. Checked 14 Nov 2026.
How is healthcare paid for in Mexico?
Public care comes through IMSS for formal workers, ISSSTE for public employees, and IMSS-Bienestar for people without social security. Source: Mexican Social Security Institute (IMSS). Checked 14 Nov 2026.
How many clinical trials on Migraine Drugs are running in Mexico?
7 studies are recruiting, active or about to start in Mexico, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Mexico. Retrieved 12 Nov 2026.
How much research is published on Migraine Drugs?
PubMed lists 60 papers on Migraine Drugs added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in Mexico

See all

Related on brain and nerves and pain

See the topic